Treatment of localized pancreatic cancer: Towards innovative and personalized treatment strategies

D. Doppenberg

Treatment of localized pancreatic cancer: Towards innovative and personalized treatment strategies

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

The first part of this thesis addresses the optimization of the interpretation and applicability of tumor markers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) in various stages of localized pancreatic ductal adenocarcinoma (PDAC). We concluded that regardless the baseline level of CA19-9, neoadjuvant therapy has a better overall survival (OS) compared to

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	Besselink, Marc, Supervisor Bruynzeel, Anna M. E., Co-supervisor, External person
Award date	8 Sept 2023
Print ISBNs	9789491014666
Publication status	Published - 2023

Access to Document

Cite this

@phdthesis{f36439da506c4dc88cb52795ccf26e9c,

title = "Treatment of localized pancreatic cancer: Towards innovative and personalized treatment strategies",

abstract = "The first part of this thesis addresses the optimization of the interpretation and applicability of tumor markers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) in various stages of localized pancreatic ductal adenocarcinoma (PDAC). We concluded that regardless the baseline level of CA19-9, neoadjuvant therapy has a better overall survival (OS) compared to",

author = "D. Doppenberg",

year = "2023",

language = "English",

isbn = "9789491014666",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - Treatment of localized pancreatic cancer

T2 - Towards innovative and personalized treatment strategies

AU - Doppenberg, D.

PY - 2023

Y1 - 2023

N2 - The first part of this thesis addresses the optimization of the interpretation and applicability of tumor markers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) in various stages of localized pancreatic ductal adenocarcinoma (PDAC). We concluded that regardless the baseline level of CA19-9, neoadjuvant therapy has a better overall survival (OS) compared to

AB - The first part of this thesis addresses the optimization of the interpretation and applicability of tumor markers carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA) in various stages of localized pancreatic ductal adenocarcinoma (PDAC). We concluded that regardless the baseline level of CA19-9, neoadjuvant therapy has a better overall survival (OS) compared to

UR - https://pure.uva.nl/ws/files/134858148/Licentieovereenkomst_medeondertekend_.pdf

UR - https://pure.uva.nl/ws/files/134858150/Propositions.pdf

M3 - Phd-Thesis - Research and graduation internal

SN - 9789491014666

ER -

Treatment of localized pancreatic cancer: Towards innovative and personalized treatment strategies

Abstract

Access to Document

Other files and links

Cite this